title: The effect of combined calcium and cholecalciferol supplementation on bone mineral density in elderly women with moderate chronic kidney disease.
abstract: OBJECTIVE
  To examine the effect of combined calcium and vitamin D3 supplementation on bone mineral density (BMD) inpatients with chronic kidney disease (CKD).
  
  
  METHODS
  We performed a post-hoc analysis of the DECALYOS II, a 2-year randomized, double-blind, placebo-controlled study of 610 women randomized to: calcium-vitamin D3 fixed combination, calcium plus vitamin D3 separate combination, or placebo. Both active treatment groups received the same daily amount of calcium (1,200 mg) and vitamin D3 (800 IU). BMD of the distal radius was measured by single X-ray absorptiometry at baseline, 12 and 24 months.
  
  
  RESULTS
  At baseline 47.2%, 36.4% and 16.4% of the study population had an eGFR ≥ 60, 45 -59, and < 45 ml/min/1.73 m2, respectively. Both active regimens vs. placebo markedly increased serum 25-hydroxyvitamin D levels from baseline in all eGFR groups (p 0.22 for all time points).
  
  
  CONCLUSIONS
  Combined calcium and vitamin D3 supplementation was effective in reducing rate of BMD loss in women with moderate CKD.
authors.affiliation: University of Washington, Division of Nephrology and Kidney Research Institute, Seattle, WA, USA.
authors.forename: Cortney
authors.initials: C
authors.lastname: Bosworth
authors.forename: Ian H
authors.initials: IH
authors.lastname: de Boer
authors.forename: Giovanni
authors.initials: G
authors.lastname: Targher
authors.forename: Jessica
authors.initials: J
authors.lastname: Kendrick
authors.forename: Gerard
authors.initials: G
authors.lastname: Smits
authors.forename: Michel
authors.initials: M
authors.lastname: Chonchol
mesh_terms: D015502:Absorptiometry, Photon; D000367:Age Factors; D000704:Analysis of Variance; D015415:Biomarkers / Q000097:blood; D015519:Bone Density / Q000187:drug effects*; D002118:Calcium / Q000097:blood / Q000627:therapeutic use*; D016009:Chi-Square Distribution; D002762:Cholecalciferol / Q000097:blood / Q000627:therapeutic use*; D002908:Chronic Disease; D019587:Dietary Supplements; D004311:Double-Blind Method; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D005260:Female; D005919:Glomerular Filtration Rate; D006801:Humans; D007326:Institutionalization; D007674:Kidney Diseases / Q000097:blood / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000503:physiopathology; D010919:Placebos; D011884:Radius / Q000000981:diagnostic imaging / Q000187:drug effects*; D013997:Time Factors; D016896:Treatment Outcome; D014807:Vitamin D / Q000031:analogs & derivatives / Q000097:blood
chemical_list: D015415:Biomarkers; D004338:Drug Combinations; D010919:Placebos; D014807:Vitamin D; D002762:Cholecalciferol; C104450:25-hydroxyvitamin D; D002118:Calcium